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Chimericain (RBD) on spike protein of severe acute respiratory syndrome-associated
coronavirus (SARS-CoV) is the main region interacting with the viral receptor-ACE2 and is a useful target for
induction of neutralizing antibodies against SARS-CoV infection. Here we generated two monoclonal
antibodies (mAbs), targeting RBD, with marked virus neutralizing activity. The mAbs recognize a new
conformational epitopewhich consists of several discontinuous peptides (aa. 343–367, 373–390 and 411–428)
and is spatially located neighboring the receptor-binding motif (RPM) region of the RBD. Importantly, W423
and N424 residues are essential for mAb recognition and are highly conserved among 107 different strains of
SARS, indicating that the residues are the most critical in the epitope which is a novel potential target for
therapeutic mAbs. A human–mouse chimeric antibody, based upon the original murine mAb, was also
constructed and shown to possess good neutralizing activity and high afﬁnity.
© 2008 Elsevier Inc. All rights reserved.Introduction
Severe acute respiratory syndrome (SARS), which spread widely in
2002 to 2004 in China and all over the world, resulted in a great loss of
life and property. This fatal disease was caused by a newly identiﬁed
coronavirus: severe acute respiratory syndrome-associated coronavirus
(SARS-CoV) (Rota et al., 2003). SARS-CoV is a new kind of coronavirus
that is signiﬁcantly different frompreviously known ones (Stadler et al.,rome; SARS-CoV, severe acute
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l rights reserved.2003). It is a single-stranded positive-sense RNA virus, which contains
four structural proteins embedded on the surface of the viral particle
(Stadler et al., 2003). Among them, it has been demonstrated that spike
protein (S protein) is the important functional protein that mediates
entry of the virus into susceptible cells. The S protein of SARS-CoV is a
type I transmembrane glycoprotein that consists of 1255 amino acids. It
has two functional domains: S1 (aa. 1–680) and S2 (aa. 681–1255) as
predicted by sequence alignmentwith S proteins of other coronaviruses
(Rota et al., 2003; Holmes, 2003).
The S1 domain mediates viral attachment to the cellular receptor
ACE2 (Li et al., 2003). The functionalportionwithin theS1domain,which
directly interacts with ACE2, has been identiﬁed as the receptor-binding
domain (RBD) (Wong et al., 2004). It is located between aa. 318–510 and
has been proven to be a major neutralizing determinant (Wong et al.,
2004; He et al., 2004a). It has been demonstrated that RBD can induce
highly potent neutralizing antibodies. Therefore, it can be considered
an excellent candidate for development of a subunit vaccine against
SARS (He et al., 2004a). Neutralizing antibodies targeting RBD can be
Fig. 1. RBD-speciﬁc neutralizing Ab was induced in mice. (A) A vaccinia virus which
contains the full length of the spike gene was used to immunize mice. Titers of the
RBD-speciﬁc Ab were tested using ELISA in sera collected 1 week after the second
immunization. ‘A’, ‘B’ and ‘C’: three individual immunized mice, ‘N’: mouse without
immunization. (B) Neutralizing activity was measured by syncytia inhibition assay.
Immunized mouse sera collected 1 week after the second booster immunization was
screened by syncytia inhibition assay. ‘No ACE2’: HEK293T cells without ACE2 plasmid
transfection. ‘+’: positive control in which HEK293T cells were transfected with ACE2
plasmid and no antiserum added. Neutralizing effects of normal mouse sera (N) and
immunized mouse sera (A, B and C) were measured in groups of ACE2 transfected
HEK293T cells. Mouse whose serum bears highest neutralizing activity was selected for
raising mAbs.
Fig. 2. Neutralizing activity of mAbs (A: N-176-15 and B: S-9-11) at different doses was
determined by syncytia inhibition assay. The method is the same as that described in
Fig. 1. ‘+’: no mAb or antiserum. ‘No ACE2’: HEK293T cells without ACE2 plasmid
transfection. ‘U’: An anti-mouse CD4mAb selected as an unrelated control. ‘S’: mAb S-9-
11, ‘N’: mAb N-176-15, the volume of mAb ascites added into eachwell (with medium of
1 ml) was also marked.
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or RBD protein (He et al., 2004a, 2004b).
Identiﬁcation of regions containing crucial amino acids within the
RBD is essential for assuring recognition of neutralizing antibodies.
Such identiﬁcation could help to increase the understanding of the
neutralizing mechanism and to aid discovery of potential drug targets.
So far, it has been reported that the RBD contains several linear and
conformational epitopes, among which, most of the neutralizing
epitopes are conformational ones (He et al., 2005). There are also some
speciﬁc fragments or crucial amino acids within the RBD region that
are related to neutralizing activity (Chakraborti et al., 2005; Yi et al.,
2005). Recently the crystal structure of the RBD and ACE2 complex
was clearly demonstrated and a receptor-binding motif (RPM aa. 424–
494) within the RBD was characterized as the important region that
directly contacts ACE2 (Li et al., 2005).
Although the studies mentioned above brought us much informa-
tion, neutralizing epitopes have still not been completely character-
ized. In particular, detailed information concerning conformational
neutralizing epitopes and critical amino acids is limited. Moreover,
recent studies have shown that the RPM is an important region
recognized by neutralizing monoclonal antibodies (Prabakaran et al.,
2006; Hwang et al., 2006). However, information on neutralizing
epitopes existing outside the RPM was still incomplete.
In this study, we generate two neutralizing monoclonal antibodies,
termed S-9-11 and N-176-15, against the RBD. They exhibit good
neutralizing activity in a syncytia inhibition assay, a pseudovirus
infection assay and a neutralization assay in SARS virus infected cells.A mapping experiment indicates that both mAbs recognize several
discontinuous peptides (aa. 343–367, 373–390 and 411–428) and that
binding activity is conformation-dependent. Mutations of W423 and
N424 completelyabrogatebindingactivityof theRBD to theneutralizing
monoclonal antibodies. It was further revealed that W423 and N424
residues within a 411–428 peptide are located adjoining the receptor-
binding motif (RBM) of the RBD, an important region holding the RBD–
ACE2 interaction surface. W423 and N424 are very stable among 107
different strains of SARS (Song et al., 2005), indicating that the mAbs
would possibly possess a broad neutralizing spectrum. Ahuman–mouse
chimeric antibodywas thus constructed based upon the N-176-15mAb.
It retained a high afﬁnity (KD=1.6×10−10M) as compared to the original
murine mAb (KD=2.8×10−9 M). In addition, it maintained binding
speciﬁcity and neutralizing activity.
The present work describes discovery of a new conformational
epitope in the RBD located outside the RPM and formed by several
discontinuous peptides with conserved amino acids W423 and N424
as critical mAb binding sites. These ﬁndings will be helpful in
development of therapeutic antibodies against SARS-CoV.
Results
Vaccinia virus induces high titers of antibodies against RBD
In order to produce a useful antigen that mimics natural Spike
protein on the particle surface of SARS-CoV, the full length S gene was
Fig. 3. (A) Neutralizing activity of mAbs (S-9-11 and N-176-15) was further conﬁrmed by
pseudovirus infection assay. ‘+’: no Ab, ‘−’: no pseudovirus infection. The dilution of the
mAb ascites and antiserum is 1:100 and 1:1000. ‘S’: S-9-11 ascites, ‘N’: N-176-15 ascites,
‘U’: an unrelated mAb ascites (anti mouse CD4). Infectivity: ‘+’ is calculated as 100% and
‘−’ as zero. (B) A denatured antigen ELISA used to determine whether the epitope is
linear or conformational. RBD-Fc denatured by heat or SDS/β-mercaptoethanol was
coated on 96-well micro-plates. ‘S’: mAb S-9-11, ‘N’: mAb N-176-15. ‘+’: RBD-Fc without
denaturation. ‘Control’: an unrelated mAb.
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conﬁrm that the expressed virus worked well, this constructed virus
was used to immunize mice and subsequent neutralizing activity of
resulting antisera was tested by a syncytia formation experiment.
Once neutralizing activity in the sera was established, the appropriate
mouse was selected for raising mAbs. To generate neutralizing mAbs
with high efﬁciency, the region covering the receptor-binding domain
(RBD) of the S gene was fused with the human IgG Fc fragment and
utilized as a screening antigen.
Experiments showed that mice immunized with the vaccinia virus
developed a remarkable antibody response against RBD protein (Fig.
1A). The antibody titer of the serum was signiﬁcantly enhanced
following booster immunization (data not shown). Oneweek after the
second immunization, antiserum was collected and tested forTable 1
Overlapping peptides covering the RBD region
1 VVPSGDVVRFPNITNL 10 KLN
2 VVRFPNITNLCPFGEVF 11 NVY
3 TNLCPFGEVFNATKFPSV 12 VKG
4 VFNATKFPSVYAWERKKI 13 IAPG
5 SVYAWERKKISNCVADY 14 GVIA
6 KKISNCVADYSVLYNSTF 15 KLPD
7 DYSVLYNSTFFSTFKCY 16 CVLA
8 STFFSTFKCYGVSATKL 17 NIDA
9 KCYGVSATKLNDLCFSNV 18 NYN
Amino acid residue sequences of overlapping peptides synthesized to cover the entire RBDneutralizing activity using the syncytia inhibition assay. The results
show that vaccinia virus immunization induces a considerable
concentration of neutralizing antibodies blocking the binding activity
between S protein and ACE2 (Fig. 1B), suggesting that the vaccinia
virus antigen could trigger signiﬁcant neutralizing antibody responses
targeting the RBD region.
mAbs possess high afﬁnity and signiﬁcant neutralizing activity
After selection, hybridoma clones reacting to the RBD domainwere
selected (data not shown), from which two clones exhibiting
neutralizing activity conﬁrmed by syncytia formation inhibition
assay (Figs. 2A and B), were chosen and termed S-9-11 and N-176-
15. When the isotypes were analyzed, S-9-11 was found to be IgG 2a
and N-176-15 to be IgG 1, both belonging to the IgG, к class. Ascites
produced with the mAbs possessed a very high titer indicated in their
binding to the RBD in ELISA, in which their dilution rates reached
1:128,000. These data demonstrate that the mAbs raised in these
studies are of very high afﬁnity and exhibit a potential inhibitory effect
in blocking the interaction of SARS-CoV Spike protein with ACE2.
Neutralizing effect of mAbs is conﬁrmed in pseudotype assay and SARS
virus infected cells
Based upon the primary data generated from syncytia inhibition
experiments, it was suggested that the S-9-11 and N-176-15 mAbs
were likely to possess potential neutralizing activity. In order to
further conﬁrm this notion, two methods were selected to evaluate
neutralizing activity. Initially, a pseudotype virus assay was utilized.
Results indicated a signiﬁcant inhibition of pseudovirus infection
achieved by use of S-9-11 and N-176-15 mAbs (Fig. 3A). The
experiments revealed that the mAbs could block the infection of
SARS pseudovirus into target Vero E6 cells through interferencewith S
protein and ACE2 interaction. Secondly, we evaluated neutralizing
activity of themAbs in SARS virus-infected FRhK-4 cells. A serial 2-fold
dilution (beginning at 1:80) was carried out to arrive at the highest
dilution rate allowing a complete suppression of CPE induced by the
virus in at least 5 of 10 wells. When mAb S-9-11 ascites was tested, it
showed a marked neutralizing effect upon SARS virus infectionwith a
dilution titer at 1:5000. In additional experiments, mAb N-176-15
ascites showed a similar neutralizing effect (data not shown). The
results strongly indicate that both S-9-11 and N-176-15 mAbs are
potentially useful candidates for therapeutic use against SARS
infection.
Mapping epitopes recognized by neutralizing mAbs
Based upon our primary data suggesting high afﬁnity and marked
neutralizing activity for S-9-11 and N-176-15 mAbs as compared to
other mAbs (data not shown), it was of interest to map epitopes
recognized by the mAbs. To do so, we ﬁrst carried out an ELISA
experiment to determine whether epitopes recognized by the mAbs
might be linear or conformational. Results showed that after RBD-FcDLCFSNVYADSFVVK 19 YLRHGKLRPFERDISNV
ADSFVVKGDDVRQIA 20 RPFERDISNVPFSPDGK
DDVRQIAPGQTGVIA 21 SNVPFSPDGKPCTPPAL
QTGVIADYNYKL 22 DGKPCTPPALNCYWPL
DYNYKLPDDFMGCV 23 PPALNCYWPLNDYGFY
DFMGCVLAWNTRNI 24 YWPLNDYGFYTTTGIGY
WNTRNIDATSTGNY 25 GFYTTTGIGYQPYRVVVL
TSTGNYNYKYRYLR 26 GYQPYRVVVLSFELLNA
YKYRYLRHGKLRPF 27 VVLSFELLNAPATVCGPK
region. The total peptide number is 27.
Fig. 4. Potential epitopes were mapped within the RBD domain. (A) Dot-blot assay for rabbit anti-S1 polyclonal antibodies. ‘+’: RBD-Fc, ‘−’: an unrelated HA peptide. (B) Dot-blot assay
of mAb N-176-15. (C) Dot-blot assay of mAb S-9-11.
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activity of mAbs with the antigen was completely lost (Fig. 3B),
indicating that the epitope is conformation-dependent.
Since the RBD domain is located at amino acid residues 318 to 510
as recognized by the mAbs, a series of synthetic overlapping peptides
(27 total) covering the entire RBD sequence were selected (Table 1)
and experiments were performed to identify speciﬁc regions or amino
acids that are crucial to the binding of themAbswith the RBD. Initially,
the synthetic peptides were coated on plates and their reactivity with
the mAbs tested by ELISA. Unexpectedly, the reactivity was undetect-
able (data not shown). Subsequently, a dot-blot experiment was
employed. To guarantee its success, we ﬁrst tested the overlapping
peptides with our laboratory-prepared rabbit anti-Spike S1 polyclonal
antibodies recognizing S1 protein from amino acid residues 1 to 678
(Wu et al., 2004). Results showed that the anti-S1 polyclonal
antibodies clearly recognized several peptides with different binding
intensities, which depended upon their different antigenicities (Fig.
4A). As expected, the pAb did not react with HA peptide (negative
control). The data demonstrated the utility of this system. From this
experiment, we were able to identify three major antigenic regions:
peptides no. 6–7 (aa. 343–367), no.10–15 (aa. 373–428), and no.19–22
(aa. 442–478) (Fig. 4A). We then tested the binding activity of the
mAbs with these peptides. Results showed that both mAbs were able
to bind the same peptides: no.6, 7, 10 and 15, which represented
amino acid residues 343–367, 373–390 and 411–428 (Table 1, Figs. 4B
and C). The no. 8 peptide position also demonstrated a mild binding
signal but was too weak to be considered recognizable. It was also
shown that the two mAbs (S-9-11 and N-176-15) recognized the same
peptides indicating they share the same epitope. Although the mAbsFig. 5. Potential crucial amino acids for binding of mAb with RBD are predicted.
Underlined letters represent amino acids recognized by the mAbs in dot-blot
experiments. Capital letters represent amino acids that were predicted by computer
model to be potentially important for the binding of the mAbwith the RBD. Combining
the results of the two methods, amino acids VAD, VL, FF, WN and RNI were selected to
be the most important amino acids determined in a site-directed mutagenesis
experiment.recognized a conformational epitope, wewere still able to use dot-blot
analysis to detect peptide reactivity and to analyze epitopes
recognized by the mAbs within the whole RBD region.
We then constructed a computer-based model of the variable
regions of mAb N-176-15 to predict its interaction pattern with the
RBD. Based upon the analysis, several clusters of amino acid residues
from the RBD were selected (Fig. 5). Combining the dot-blot
experiment and the computer prediction, we predicted that ﬁve
sites (VAD, VL, FF, WN, RNI) might be important for mAb binding (Fig.
5). A site-directed mutation experiment was then carried out to test
whether the putative sites could inﬂuence their binding. We mutated
the amino acids of the ﬁve sites into alanines (Table 2), generated
mutated RBD-Fc with transient transfection and determined their
binding activity with the mAbs using a sandwich ELISA (Fig. 6). The
results show that the W423 and N424 mutated RBD-Fc lost
signiﬁcant ability to bind with the mAbs, indicating that these two
amino acids are crucial for the binding of mAbs N-176-15 and S-9-11
with the RBD.
Finally, we determined the degree of variation of these two amino
acid residues in different SARS strains.We chose 107 SARS spike genes,
amongwhich 14 are from palm civet (4 from 2003, other 2004) and 93
from human (4 from 2004, 11 from early 2003, 17 from middle 2003,
61 from late 2003) (Song et al., 2005). The W423 and N424 are very
conserved in all SARS S gene sequences without any mutation. The
results indicate that the mAbs would probably have a broad viral
neutralizing spectrum and that this epitope is highly conserved
among different SARS strains.
The structure of the RBD offered a direct andmore precise proﬁle of
this newly identiﬁed neutralizing epitope. Peptides identiﬁed in dot-Table 2
Primers for site-directed mutagenesis; construction of RBD-Fc expressing plasmids
aa. residues
mutated
Primer sequences
FF→AA SP: TAC AAC TCA ACA GCT GCT TCA ACC TTT AAG
AS: CTT AAA GGT TGA AGC AGC TGT TGA GTT GTA
WN→AA SP: TGT GTC CTT GCT GCT GCT ACT AGG AAC ATT
AS: AAT GTT CCT AGT AGC AGC AGC AAG GAC ACA
VL→AA SP: GCT GAT TAC TCT GCT GCT TAC AAC TCA ACA
AS: TGT TGA GTT GTA AGC AGC AGA GTA ATC AGC
VAD→AAA SP: AAA ATT TCT AAT TGT GCT GCT GCT TAC TCT GTG CTC TAC
AS: GTA GAG CAC AGA GTA AGC AGC AGC ACA ATT AGA AAT TTT
RNI→AAA SP: CTT GCT TGG AAT ACT GCT GCT GCT GAT GCT ACT TCA ACT
AS: AGT TGA AGT AGC ATC AGCAGC AGC AGT ATT CCA AGC AAG
The candidate amino acid residuesweremutated to alanineswithin theprimersdesigned
for mutation. SP: sense primer. AS: anti-sense primer.
Fig. 8. Chimeric antibody recognition of the peptides recognized by N-176-15 tested in
dot-blot. ‘+’: RBD-Fc, ‘−’: an unrelated HA peptide.
Fig. 6. Identiﬁcation of potentially important amino acids by site-directed mutagenesis
for the binding of the mAbs with the RBD. ELISA was used to measure the binding
activity of the mAbs with the RBD or with mutated RBD generated from supernatants of
HEK293T cells transfected with RBD-Fc plasmid or mutated RBD-Fc plasmids. ‘+’:
supernatant of RBD-Fc plasmid transfection, ‘RBD-Fc’: puriﬁed RBD-Fc protein
dissolved in distilled water at a concentration of 20 μg/ml, ‘−’: supernatant of cells
without transfection. ‘VAD’ etc.: ﬁve mutated RBD-Fc proteins (selected amino acids
mutated to alanine) expressed in cell culture supernatants. (A) Reaction measured by
mAb S-9-11. (B) Reaction measured by mAb N-176-15.
Fig. 7. Spatial location of the epitope predicted using a computer-analysis model. Green:
ACE2, Magenta: RBD. The location of binding peptides and amino acidsW423, N424 are
marked as blue: aa. 343–367, cyan: aa. 373–390, orange: aa. 411–428, wheat: W423 and
N424.
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immediately beside the RPM region (Fig. 7). Interestingly, N424was the
ﬁrst amino acid residue determined for the RPM (Li et al., 2005).
Although this neutralizing epitopewas notwell localized on the surface
that directly contacts ACE2, antibodieswere able to bind this region and
block the attachmentofACE2due to spatial hindrance. This explains the
neutralization mechanism of the two mAbs at a molecular level.
A chimeric antibody shows a potential blocking effect on SARS-CoV
infection
We constructed a chimeric antibody based upon the N-176-15
clone, and retaining the afﬁnity, speciﬁcity and neutralizing activity of
the murine mAb. As the data shows, the chimeric antibody recognizes
the same peptides as does the murine antibody in the dot-blot assay,
indicating that the chimeric nature of the antibody does not change its
binding speciﬁcity (Fig. 8). A SPR experiment was carried out to
determine the binding afﬁnity of the chimeric antibody with the RBD.
The data indicates that both the chimeric antibody and the murine
mAb show a very high binding afﬁnity with the RBD, their KDs being
1.6×10−10 M and 2.0×10−9 M respectively. This high afﬁnity explains
the strong neutralizing effect of the mAb. There is no doubt that the
constructed chimeric antibody completely preserves the binding
afﬁnity of the murine mAb. In addition, we tested the neutralizingactivity of the chimeric antibody in the pseudovirus infection system.
The results reveal that the chimeric antibody has a similar function to
the murine one in completely blocking entry of the pseudovirus into
Vero E6 cells at a concentration of 1 μg/ml (data not shown). All data
indicate that we have successfully constructed a SARS chimeric
neutralizing antibody with great potential for therapeutic use against
SARS infection.
Discussion
From this study, it is demonstrated that the receptor-binding
domain of SARS-CoV plays a crucial role in the process of viral
infection and host immune response, especially as a dominant antigen
in inducing neutralizing antibody development.
Information concerning epitopes on the RBD has been reported. It
has been revealed that the RBD contains various linear and
conformational epitopes and that most of the neutralizing epitopes
are conformational ones (He et al., 2005). Although the neutralizing
antibodies show a higher afﬁnity, the spatial proﬁles of these
conformational epitopes had not been well understood. There have
also been some studies on functionally important amino acids or
segments of the RBD. It was reported that the deletion of a positively
charged region (422–463) on the RBD protein abolished the capacity
of the S protein to induce neutralizing antibodies (Yi et al., 2005). It
was also reported that a single amino acid substitution (R441A) in the
full-length S DNAvaccine failed to induce neutralizing antibodies or to
abolish viral entry (Yi et al., 2005). These results indicated that
particular portions of and amino acids on the RBD are crucial for
retaining the RBD's normal function. However, whether critical amino
acids or segments exist in conformational neutralizing epitopes was
still not known. The crystal structure of the RBD–ACE2 complex has
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structure and function (Li et al., 2005). The structure revealed that the
RBD could be further divided into 2 separate subdomains. One is the
RBD core and the other is the RBD loop (RPM) (aa. 424–494). The RBD
loop is the region that directly contacts the ACD2 molecule. The RBD
core, on the other hand, makes contact with accessory proteins (Li et
al., 2005). The epitope recognized by a humanized neutralizing
monoclonal antibody, 80R, has been mapped and its crucial amino
acid residues on the RBD loop region binding to the neutralizing mAb
has been determined (Sui et al., 2004, 2005). However, little evidence
or description was reported regarding epitopes, especially conforma-
tional ones, located outside the RBD loop region.
Currently an important task is to characterize neutralizing
epitopes, to clarify their spatial proﬁle and to determine important
regions or amino acids involved in neutralizing antibody recognition.
Because most neutralizing epitopes are conformational ones, it is
more meaningful to develop a suitable strategy by studying their
structure and then identifying the critical amino acids in a given
antigen.
In this study, we report, for the ﬁrst time, a conformational
neutralizing epitope localized outside the RPM region, indicating that
neutralizing antibodies do not bind only the surface of RBD–ACE2
interaction but also bind other sites. Ultimately, three peptides (aa.
343–367, 373–390 and 411–428) are seen to form a conformational
epitope; within them the amino acids W423 and N424 in the 411–428
peptide, are a central point for mAb recognition and for eliciting
neutralizing antibodies.
In this research process, it is notable that a peptide-related dot-blot
method was used to analyze conformational epitopes. The results
indicate that a neutralizing mAb that recognizes a natural-conforma-
tion-dependent antigen can bind in mild afﬁnity with peptides that
could only be detected by the dot-blot method.
Many clones of neutralizing monoclonal antibodies with the target
of S protein have been raised so far. A variety of methods have been
utilized; for example, the traditional PEG cell fusion method and the
phagedisplaymethod (Sui et al., 2004; Chouet al., 2005; andBrinket al.,
2005). Antigens for immunization include inactivated whole virus,
recombinant S protein and RBD-Fc protein (He et al., 2004b; Chou et al.,
2005; and Zhou et al., 2004). Here we used a modiﬁed recombinant
vaccinia virus Ankara with SARS S protein on the surface as the antigen
with which to immunize mice. The results show that this vaccinia virus
was able to elicit high titers of neutralizing antibodies (Chen et al.,
2005). Therefore, it appears to be an ideal immunizing antigen for
generation of monoclonal antibodies as well as a possible vaccine
candidate. For screening of hybridoma clones, we usedmammalian-cell
expressed RBD-Fc protein, whose natural conformation is well
preserved. With this strategy, we successfully obtained two hybridoma
clones generatingmonoclonal antibodies to target the RBD regionof the
S protein with high afﬁnity and good neutralizing effect.
For the evaluation of neutralizing effects, we utilized two different
systems, one a syncytia inhibition assay, and the other a pseudovirus
infection assay. These procedures allowed us to evaluate the
neutralizing effects of antibodies or peptides conveniently in vitro.
Since the W423 and N424 amino acids in the neutralizing epitope
constitute a conserved site and the mAb against the site thus
constitutes a potential therapeutic mAb, we constructed a chimeric
antibody based upon the murine monoclonal antibody N-176-15
clone. The chimeric antibody is shown to have the same speciﬁcity as
the original murine one and retains its neutralizing effect. Therefore,
our work demonstrates the feasibility of constructing neutralizing
chimeric antibodies with potential therapeutic value that might be
further developed into SARS therapeutic drugs.
In summary, mAbs recognizing a new conformational epitopewere
raised, the epitope consisting of several discontinuous peptides (aa.
343–367, 373–390 and 411–428) and spatially located near the
receptor-binding motif (RPM) region of the RBD. The W423 andN424 residues in the 411–428 peptide are essential for mAb
recognition and are highly conserved among 107 different strains of
SARS, indicating that the residues are the most critical in the epitope
and constitute a novel potential target for inducing a broad response
from neutralizing mAbs. A human–mouse chimeric antibody was also
constructed with good neutralizing activity and high afﬁnity based
upon the original murine mAb. The characteristics demonstrated for
such a mAb demonstrate a notable potential for use in prevention of
SARS infection.
Materials and methods
Animals
Balb/c mice were purchased from Shanghai Laboratory Animal
center, Chinese Academy of Sciences. Animals were kept in conven-
tional conditions and were handled in compliance with Chinese
Academy of Sciences guidelines for Animal Care and Use.
Antigen for immunization
Recombinant modiﬁed vaccinia virus Ankara expressing the S
protein of SARS-CoV was used as the antigen for immunization (Chen
et al., 2005). This modiﬁed SARS vaccine showed excellent potential to
induce neutralizing antibodies that target primarily the RBD region.
Mammalian-cell expressed RBD-Fc serves as a natural form of protein
of the RBD region (He et al., 2005) and was used as an antigen for
screening hybridoma clones.
Immunization of mice and generation of monoclonal antibodies
Six-week old female Balb/c mice were used for immunization. For
each injection, the quantity of antigen used per mouse was 5×107 pfu
and an intramuscular multi-site injection method was adopted.
Boosting was carried out 4 times, each at 3-week intervals. Serum
was collected 3 days after the second immunization and was stored at
−20 °C. Three days after the last boost, mouse spleen cells were
harvested and fused with myeloma cell lines NS-1 and SP2/0 using
50% PEG (w/v) and were distributed in 96-well plates. Culture
supernatants from each well were screened using ELISA for antibody
reactivity against the RBD. Positive wells were then selected using a
limiting dilution method. After three cycles of cloning, hybridoma
clones were established. Monoclonal antibody isotypes were identi-
ﬁed using a mouse sub-isotyping kit (Bio-Rad USA). Monoclonal
antibodies were produced from mouse ascites by injection of 106
hybridoma cells per mouse intraperitoneally and were puriﬁed by
Protein G column chromatography.
ELISA
RBD-Fc protein dissolved in 0.1 M carbonate buffer (pH 9.6) was
coated on 96-well micro-titer plates (10 μg/ml, 50 μl/well) at 4 °C
overnight. After blocking with phosphate-buffered saline (PBS)
containing 10% bovine serum and 0.1% Tween 20 at 37 °C for 2 h, the
plates were incubated with culture supernatants or diluted antiserum
at 37 °C for 2 h. Bound antibodies were detected with HRP-conjugated
goat anti-mouse Ig antibody (Santa Cruz USA). Tetramethylbenzidine
(TMB) was used as substrate (Sigma USA), and the absorbance was
measured using a micro-titer plate autoreader (Thermo USA) at
450 nm. In a sandwich ELISA, protein G puriﬁed S-9-11 or N-176-15
mAbs were coated on 96-well micro-titer plates. After blocking,
supernatant containing RBD-Fc or its mutated form was placed into
the plates; an anti-human IgG (Fc speciﬁc) HRP-conjugated antibody
(Sigma USA) was used as detecting antibody in a detailed protocol
as described above. In an RBD denatured ELISA, RBD-Fc protein and
RBD-Fc protein denatured with heat (80 °C10 min) or 5%SDS+5%β-
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and incubated at 4 °C overnight in a detailed protocol as described
as above.
Syncytia inhibition assay
This assay was described in our previous article (Lu et al., 2005). In
brief, we co-transfected HEK293T cells (approximately 50% conﬂuent
in 60 mm dishes) with plasmids pCDNA3.1-ACE2 and pUHD 15-1
(SV40), while another group of HEK293T cells (approximately 50%
conﬂuent in 60 mm dishes) were co-transfected with pCDNA3.1-
spike-Ig and pUHD 10-3(Luc). A control plasmid, pRellina, was also
utilized as an internal reference. Twenty-four hours after transfection,
the two groups of cells were trypsinized, re-suspended in DMEM/10%
FBS and adjusted to a proper ﬁnal concentration. The antibody ascites
or antiserum obtained during mAb generation was added to the spike
protein group of transfected cells at serial doses of 10, 20 or 40 μl per
well and incubated for 0.5 h at 37 °C. Subsequently, the two groups of
cells were mixed together (cell number 1:1) in 48-well plates with a
total cell number of 4×105, a volume of 1 ml per well and were
incubated at 37 °C. Twenty-four hours later, medium was aspirated
and cells were lysed with passive lysis buffer (Promega USA).
Luciferase intensity was measured using a luminometer TD-20/20
(Promega USA).
Pseudovirus infection assay
HEK293T cells were plated at approximately 50% conﬂuence in 6-
well plates. Twenty-four hours later, plasmids coding SARS spike
protein and pNL4-3 luc Env− Vpr− were co-transfected using
lipofectamine (Invitrogen USA) to generate an HIV backbone pseudo-
virus with SARS spike protein embedded on the surface (Chen et al.,
2005). Forty-eight hours later, supernatant was collected from the
cells using low speed centrifugation (3000 rpm, 5 min), aliquoted and
frozen at −140 °C. Vero E6 cells were plated as target cells before
infection in 24-well plates at approximately 50% conﬂuence. During
infection, medium was aspirated and 100 μl pseudovirus (super-
natants) mixed with 900 μl 12% FBS/DMEM added per well
simultaneously with or without puriﬁed mAb, ascites or antiserum
at 37 °C for incubation. Twenty-four hours later, another 1 ml of 12%
FBS/DMEMwas added to eachwell. Seventy-two hours after infection,
medium was aspirated, cells were washed with PBS twice, lysed with
passive lysis buffer (Promega USA) at room temperature, and stored at
−80 °C or analyzed immediately for luciferase activity.
SARS virus neutralization assay
Micro-titer plates were used in the neutralization assay. Serial two-
fold dilutions (1:80 to 1:10,240) of mAb were separately mixed with
100 TCID50 of virus (GZ50), incubated at 37 °C for 1 h and then added to
FRhK-4 cells. A virus back-titration (virus in serial two-fold dilution
with medium), virus positive control (100 TCID50) and negative cell
controls with medium in parallel with the neutralization test were
included in the assay. Each dilution of serum or virus control was
repeated in 10 wells. Results were observed daily and CPE endpoints
were read and recorded up to 3 days after virus inoculation. The TCID50
was calculated using the Reed–Muench method. The titer of the
neutralization antibody was determined based upon the highest
dilution of the mAb at which the mAb could completely suppress CPE
induced by the virus in at least 5 of 10wells. All virus experimentswere
carried out in a bio-safety P3 laboratory at theUniversity of HongKong.
Dot-blot analysis
This assay was performed to identify binding epitopes of the
monoclonal antibodies. Antigens used were overlapping peptidescovering the entire RBD domain (aa. 318–510). For each peptide, 5 μg
diluted in 50 μl PBS was blotted on PVDF membrane, which was then
washed ﬁve times in TTBS. The membrane was blocked in 3% BSA (in
TTBS) at 37 °C for 2 h. Diluted monoclonal antibody or antiserum in 3%
BSA (in TTBS) was then added and incubated at 4 °C overnight.
Subsequently, the membrane was incubated with a secondary anti-
body (goat anti-mouse/rabbit HRP conjugated antibody (Santa Cruz
USA)) at 37 °C for 1 h. The blots were developed using ECL western
blotting substrate reagents (Pierce USA).
Bioinformatic analysis
A computer-based simulation of the structure of the N-176-15
VH/VL region and construction of the interaction model of this
structure with the RBD domain was carried out to determine speciﬁc
amino acids critical for binding activity. We ﬁrst cloned the variable
region of the N-176-15 mAb. With the sequence and PDB database, a
structure model was constructed; the binding model of the putative
structure with the already-known RBD structure was simulated and
potentially crucial amino acids were predicted.
Site-directed mutagenesis
A PCR method was used to construct mutated forms of the RBD
protein. The mutated amino acids were constructed utilizing PCR
primers. After PCR, mutated forms of the RBD genewere obtained and
subsequently cloned into a pCDNA3.1 vector with a human IgG Fc tag
gene. The mutated amino acids and the speciﬁc PCR primers are
included in Table 2. A transient mammalian protein expression system
was used to express the RBD protein and its mutated form. Brieﬂy, the
RBD-Fc expression plasmid was transiently transfected using lipofec-
tamine (Invitrogen USA) into HEK293T cells, plated 24 h before in 6-
well plates. Forty-eight hours later, cellswere harvested and lysedwith
0.5 ml RIPA buffer per well. Supernatants were collected after
centrifugation at 12000 rpm for 10 min. Using the sandwich ELISA
assay described above, it was possible to successfully detect mAb
binding activity to RBDor to itsmutated form in cell lysis supernatants.
Chimeric antibody construction and characterization
To construct a mouse–human chimeric IgG, total RNA was isolated
from N-176-15 hybridoma cells using TRI Reagent (Sigma USA). The
variable domain gene was obtained by a 5′RACE polymerase chain
reaction (5′RACE PCR), reverse transcription and gel puriﬁcation.
Subsequently, the gene was inserted into a pGEM-T Vector (Promega
USA) and sequenced (Sangon China). The variable region gene
including signal sequence was constructed in a WS3 plasmid
containing a human kappa constant domain and a human CH1–
CH2–CH3 domain. The plasmid was then transfected into CHO-dhfr−
cell lines using lipofectamine reagent (Invitrogen USA) to construct
chimeric-antibody-secreting cells. Clones were screened using ELISA
to detect chimeric antibody in culture supernatant and were
established using a limiting dilution method. After establishment of
stably transfected clones, a dot-blot procedure was used to measure
the binding speciﬁcity of the chimeric antibody and a SPR (Biacore
USA) assay was employed to characterize its afﬁnity. A pseudovirus
infection assay was used to determine neutralizing activity of the
chimeric antibody.
Statistical analyses and reproducibility
Experiments were repeated at least twice, and usually three or
more times. Figures show data compiled from several experiments, or
from a representative experiment, as speciﬁed. Results represent the
mean±SD where applicable. Statistical analyses for parametric data
were performed by independent t-test.
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